Hormonal
Blocking IL-6 trans-signaling (but not classical signaling) using soluble gp130 (sgp130) or anti-IL-6R antibodies can prevent muscle wasting in cachexia without impairing beneficial immune responses.
For patients with severe muscle wasting due to disease, emerging treatments focus on blocking specific inflammatory pathways (trans-signaling) rather than broadly suppressing the immune system. This approach aims to stop muscle loss while preserving necessary immune defenses. Consult an oncologist or specialist for eligibility for such targeted therapies.
Here we discuss on potential therapeutic strategies using monoclonal antibodies to IL-6R for the treatment of skeletal muscle wasting and cachexia.
Why this rating
The paper discusses potential strategies and mechanisms but notes that future investigations are needed; it is a review of preclinical/conceptual data.
Source
Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6
José Ernesto Belizário et al. · SpringerPlus · 2016
DOI 10.1186/s40064-016-2197-2
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →